JASON GARDNER Insider Profile
4 Followers
JASON GARDNER, President & CEO, Director at Dianthus Therapeutics, holds 944.95K shares in Dianthus Therapeutics (Ticker: DNTH).
JASON GARDNER's Trading History
| DNTHDianthus Therapeutics | Dec 02, 2022 | President & CEO, Director | Uninformative Buy | 2.82K | $86.76M | |
DNTH Insider Shares: 944.95K (1.56%) | ||||||
You May Also Like
JASON GARDNER insider profile FAQ
What is the percentage of profitable transactions made by JASON GARDNER?
The percentage of profitable transactions made by JASON GARDNER is 100%.
What is the average return per transaction made by JASON GARDNER?
The average return per transaction made by JASON GARDNER is 41.30%.
What stocks does JASON GARDNER hold?
JASON GARDNER holds: DNTH stocks.
What was JASON GARDNER’s latest transaction?
JASON GARDNER’s latest transaction was an Uninformative Buy of $2.82K.
What was JASON GARDNER's most profitable transaction?
JASON GARDNER’s most profitable transaction was an Informative Sell of DNTH stock on September 20, 2021. The return on the trade was 77.80%.
What is JASON GARDNER's role in Dianthus Therapeutics?
JASON GARDNER's role in Dianthus Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
